S. Jeson Sangaralingham, MS  PhD

Senior Scientific Advisor

Dr. Sangaralingham is an Associate Professor of Medicine and Physiology, Associate Director of the Department of Cardiovascular Medicine’s NIH T32 Training Program, and faculty member in the Cardiorenal Research Laboratory at Mayo Clinic. He also serves on the Scientific Advisory Board of Mayo Clinic’s Cardiovascular Research Center.  His NIH-funded and translational research program is focused on the role of the natriuretic peptide/particulate guanylyl cyclase/cGMP (NP/GC/cGMP) signaling pathways to protect against adverse cardiorenal remodeling, fibrosis and dysfunction.

He has a long interest in novel NP-based biomarker discovery and the engineering of innovative GC/cGMP enhancing therapeutics has led to 32 issued and pending patents worldwide and the formation of one biotech company.

He has received the Jay N. Cohn New Investigator Physiology/Clinical Award from the Heart Failure Society of America for his research contributions, and he is recognized as a Fellow of the American Heart Association. Dr. Sangaralingham received his M.S. and Ph.D. from Queen’s University Kingston, Ontario, Canada and completed his postdoctoral research fellowship at Mayo Clinic.